Membrane-Free Alveolus-on-a-Chip via Biodegradable Scaffold Recapitulates Interstitial Mechanics, Immune Trafficking, and Aerosolized mRNA Delivery

This study presents a membrane-free human alveoli-on-a-chip utilizing a biodegradable PLGA scaffold that is replaced by fibroblast-derived ECM to recapitulate native interstitial mechanics, thereby preventing stiffness-induced fibrosis, enabling immune cell trafficking, and facilitating efficient aerosolized mRNA delivery.

The Gist

Imagine your lungs are a vast, bustling city made of millions of tiny, balloon-like rooms called alveoli. These are the places where your blood picks up fresh oxygen and drops off carbon dioxide. In a healthy city, these rooms have a very specific, delicate architecture: a thin skin on the outside (epithelium), a thin skin on the inside (blood vessels), and a tiny, flexible "neighborhood" in between made of living cells and a soft, stretchy mesh called the extracellular matrix (ECM).

For years, scientists trying to study these lungs in the lab have been using a very clumsy tool: a plastic sandwich bag. They grow lung cells on a permanent, stiff plastic membrane. It holds the cells up, but it's like trying to study a living, breathing forest by planting trees in a concrete slab. The plastic is too hard, it doesn't breathe like real tissue, and it stops the cells from talking to each other naturally.

This new paper introduces a brilliant solution: A "Self-Dissolving" Lung Chip.

Here is how it works, broken down into simple concepts:

1. The "Temporary Scaffold" (The Plastic that Disappears)

Instead of a permanent plastic wall, the scientists built a tiny, dome-shaped scaffold out of a special, biodegradable plastic called PLGA. Think of this like a sugar castle built to hold up a structure while the real bricks are being laid.

• The Setup: They put lung cells (fibroblasts) on this sugar castle.
• The Magic: Over about 10 days, the sugar castle slowly dissolves in the water.
• The Result: As the plastic disappears, the lung cells rush in to fill the gap, laying down their own natural, soft, stretchy mesh (the ECM). By the time the plastic is gone, the cells have built their own "neighborhood" from scratch. It's like the construction crew building the real house while the temporary scaffolding falls away.

2. Why the "Concrete" Was Bad (The Stiffness Problem)

The paper found that the old, permanent plastic membranes were actually hurting the cells.

• The Analogy: Imagine trying to relax on a bed made of concrete versus a memory foam mattress.
• The Science: The hard plastic "concrete" made the lung cells feel stressed. They thought, "This place is too hard! We need to get tough!" So, they turned into myofibroblasts (stiff, angry cells) and started producing toxic waste (ROS) that killed their neighbors (the lung lining cells).
• The Fix: The new "Self-Dissolving" chip is soft and flexible. Because it feels like a real, soft lung, the cells stay calm, healthy, and do their job properly.

3. The "Immune Police" Can Now Patrol

In a real lung, immune cells (like monocytes) need to be able to squeeze through the walls to fight infections.

• The Old Way: The permanent plastic wall was like a locked gate. The immune cells couldn't get through, so the model didn't work for studying infections.
• The New Way: Because the new chip is made of living cells and a soft mesh (not a solid plastic wall), the immune cells can naturally migrate through it, just like they do in your body. The scientists even showed that when they called for help (using a chemical signal), the immune cells marched right through the barrier to the other side.

4. Delivering Medicine via "Aerosol Mail"

Finally, the scientists tested if they could send medicine into this tiny lung. They used a special type of nanoparticle (a tiny delivery truck) made of Metal-Organic Frameworks (MOFs).

• The Test: They sprayed these nanoparticles onto the "lung" like a mist.
• The Result: The particles successfully delivered genetic instructions (mRNA) to the cells inside the lung. They were able to get past the "surfactant" (the soapy film that covers real lungs) and deliver the message to both the surface cells and the deep neighborhood cells.
• Safety: The "mail" didn't hurt the cells; they stayed alive and healthy.

The Big Picture

This new "Membrane-Free Alveolus-on-a-Chip" is a huge leap forward. It's like swapping a mannequin for a living, breathing actor.

• Old Model: A stiff, plastic wall that kills the cells' natural behavior.
• New Model: A self-building, soft, living environment where cells act like they are in a real human lung.

This tool will help scientists study lung diseases (like fibrosis, where lungs get scarred and stiff), test new drugs for asthma or pneumonia, and figure out how to deliver gene therapies to the lungs without hurting the patient. It's a much more realistic, "human-like" way to study our most vital organs.

Technical Summary

1. Problem Statement

Current lung-on-a-chip platforms typically rely on permanent synthetic membranes (e.g., Transwell inserts) to separate epithelial and endothelial layers. These artificial barriers fail to recapitulate the native alveolar interstitium, which is a dynamic, biological microenvironment composed of extracellular matrix (ECM), lung fibroblasts, and interstitial fluid.

• Limitations of existing models:
  • They lack the physiological mechanical properties (stiffness) of the native interstitium.
  • They prevent direct cell-cell contact and signaling between fibroblasts and epithelial cells.
  • They do not support complex immune cell trafficking (transmigration) across the barrier.
  • Rigid synthetic substrates often induce pathological phenotypes, such as fibroblast-to-myofibroblast differentiation, leading to fibrosis-like responses that confound experimental results.
  • They are suboptimal for testing aerosolized nanomedicine delivery due to the artificial barrier properties.

2. Methodology

The authors developed a membrane-free human alveoli-on-a-chip using a biodegradable scaffold strategy to reconstruct the interstitial niche.

• Scaffold Fabrication:

  • Material: Poly(lactic-co-glycolic acid) (PLGA), chosen for its biodegradability and biocompatibility.
  • Architecture: A dome-like, porous structure (~200 µm diameter) mimicking the alveolar geometry was created using a dual-templated nonsolvent-induced phase separation (NIPS) method. Camphene crystals acted as a sacrificial porogen to create a highly porous network.
  • Degradation Strategy: The PLGA membrane is designed to degrade hydrolytically over ~10 days. As it degrades, it is progressively replaced by ECM deposited by cultured lung fibroblasts.

• Cell Culture Protocol:

  • Step 1: Primary human lung fibroblasts are seeded on the apical side of the PLGA membrane and cultured until a confluent monolayer forms.
  • Step 2: As the PLGA degrades, fibroblasts deposit ECM (Collagen I, Fibronectin), bridging the gap left by the dissolving scaffold.
  • Step 3: Human alveolar epithelial cells (A549, Type II-like) are seeded on top of the fibroblast layer.
  • Step 4: The system is switched to Air-Liquid Interface (ALI) conditions to promote epithelial maturation and surfactant secretion.
  • Immune Integration: THP-1 monocytes (differentiated into macrophages) and monocytes were introduced to study immune trafficking and integration.

• Comparative Controls:

  • Experiments were compared against rigid Transwell® inserts and non-degradable PCL membranes to isolate the effects of substrate stiffness and membrane presence.

• Nanomedicine Testing:

  • Aerosol Delivery: Metal-Organic Framework (MOF) nanoparticles and Lipid Nanoparticles (LNPs) carrying GFP-encoding mRNA were aerosolized onto the chip.
  • Analysis: Transfection efficiency, cell viability, cytokine secretion, and ROS levels were measured.

3. Key Contributions

1. Dynamic Interstitial Reconstruction: The first platform to transition from a synthetic scaffold to a biologically formed interstitial layer (fibroblast-derived ECM) that maintains structural integrity after the scaffold disappears.
2. Mechanical Decoupling: Demonstrated that removing the rigid synthetic substrate prevents stiffness-driven myofibroblast activation, thereby preserving a more physiological cellular state.
3. Immune Trafficking Model: Successfully recapitulated chemokine-driven monocyte transmigration across the alveolar barrier, a process blocked in conventional membrane-based systems.
4. Nanomedicine Platform: Validated the chip as a physiologically relevant model for testing aerosolized mRNA delivery, showing that MOF nanoparticles can penetrate the surfactant layer and transfect both epithelial and interstitial cells.

4. Key Results

• Structural Evolution:

  • The PLGA membrane degraded over 10 days, increasing porosity from 19.5% to ~43.5% and forming a central pore (200 µm).
  • Fibroblasts maintained a continuous layer and bridged the degraded regions, secreting Collagen I and Fibronectin.
  • Critical Finding: Without the fibroblast layer, epithelial cells failed to maintain continuity after membrane degradation, proving the ECM's structural necessity.

• Mechanical & Phenotypic Regulation:

  • Stiffness: The PLGA membrane modulus (8.55 MPa) was ~47-fold lower than Transwell® inserts.
  • Myofibroblast Activation: Fibroblasts on rigid Transwell® substrates showed high $\alpha$-SMA expression (myofibroblast marker), whereas those on the degrading PLGA/membrane-free system showed minimal activation.
  • Cellular Health: The rigid Transwell® system led to elevated Reactive Oxygen Species (ROS), increased epithelial cell death, and compromised barrier integrity (lower TEER, higher permeability). The membrane-free system preserved epithelial viability and barrier function.

• Epithelial Maturation:

  • Direct contact between fibroblasts and epithelial cells on the chip significantly upregulated Surfactant Protein C (SPC) and LAMP3 (lamellar body marker) compared to monocultures or non-contact co-cultures.

• Immune Cell Trafficking:

  • In the presence of MCP-1 (chemokine), monocytes successfully migrated across the epithelial-fibroblast barrier in the membrane-free chip.
  • Migration was virtually absent in Transwell® and PCL systems due to the impermeable synthetic barrier.

• Aerosolized mRNA Delivery:

  • MOF vs. LNP: MOF nanoparticles successfully delivered mRNA to both epithelial and fibroblast layers. LNPs primarily transfected fibroblasts beneath the epithelium but failed to efficiently transfect the epithelial layer itself.
  • Macrophage Impact: The presence of macrophages reduced overall transfection efficiency (due to phagocytosis), accurately mimicking the "first-line defense" clearance mechanism of the lung.
  • Safety: MOF delivery showed high cell viability (>91.9%) and only modest inflammatory responses (elevated MCP-1 and IL-6, but no severe toxicity).

5. Significance

This study bridges a critical gap between in vitro models and in vivo physiology by addressing the mechanical and biological complexity of the alveolar interstitium.

• For Disease Modeling: The platform offers a superior model for studying fibrosis, as it avoids the artificial stiffening that triggers fibrotic pathways in conventional chips.
• For Immunology: It enables the study of immune cell recruitment and trafficking in a native-like 3D environment.
• For Drug Development: It provides a high-fidelity screening tool for inhaled therapeutics (e.g., mRNA vaccines, gene therapies), accounting for the surfactant barrier, immune clearance, and interstitial cell targeting.

By replacing the static synthetic barrier with a dynamic, cell-replaced ECM, this membrane-free alveoli-on-a-chip represents a paradigm shift in pulmonary tissue engineering, offering a more predictive platform for pulmonary biology and nanomedicine.